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ANTIBACTERIAL ACTIVITY OF
SILVER-GRAPHENE QUANTUM DOTS
NANOCOMPOSITES AGAINST
GRAM-POSITIVE AND GRAM-NEGATIVE
BACTERIA
GOVERNMENT INTEREST
The claimed invention was made with U.S. Government
support under grant numbers 1002410 and 0841338 awarded
by the National Science Foundation (NSF) and grant number
NNX13AB22A awarded by the National Aeronautics and
Space Administration (NASA). The government has certain
rights in this invention.
BACKGROUND OF THE INVENTION
Microbial infections are considered a major health prob-
lem with a growing concern toward those that do not
respond to treatment due to antibiotic-resistant bacteria.
According to the U.S. Centers for Disease Control and
Prevention, approximately two million people are infected
annually with bacteria resistant to antibiotics, of which ca.
23000 people die as a direct result of these infections. The
prevention and treatment of these infections has drawn
considerable attention and presents a critical challenge to
develop drugs, antibiotics and/or antibacterial substances
able to inhibit bacterial growth.
Infections due to Gram-negative Pseudonomas aerugi-
nosa (P. Aeruginosa) and Gram-positive Staphylococcus
aureus (S. aureus) have been documented in surgical sites,
where they have been attributed to dermal injuries and burn
wounds. Gram-negative bacteria are characterized by a
lipid-rich outer membrane as well as a plasma membrane
and a thin peptidoglycan layer, while Gram-positive bacteria
are enshrouded in thicker, more resilient cell walls. This
difference in cell wall is important for antibiotic develop-
ment, since bacterial resistance might be due in part to cell
wall composition.
Several conventional antibacterial agents, such as: tetra-
cycline, streptomycin, and sulfonamides, have been devel-
oped to inhibit bacterial infections via the formation of
biofilms. However, these antibiotics failed to inhibit all types
of bacteria and multidrug-resistant strains have appeared due
to the pathogen's evolution in counteracting the biocidal
action of the agent molecules. Consequently, it is necessary
to develop antibiotics that can overcome the limitations of
the conventional antibacterial agents and preferably work
against both types of bacteria. Interestingly, materials such
as: silver nanoparticles, copper oxide, carbon nanomaterials,
and metal oxide nanoparticles, have been reported as anti-
microbial agents, and have been considered for use in wound
infections, and in the clothing industry. In specific, silver is
widely recognized for its capacity to kill bacteria. The
mechanism of silver as an antibacterial agent is not totally
clear, but it includes some possible mechanisms, such as:
denaturation of the 30 s ribosomal subunits, inhibition of
respiratory enzymes, binding and dimerization of RNA and
DNA, and disruption of the outer membrane. Nevertheless,
silver has shown high levels of toxicity at adequate concen-
trations for its antibacterial use.
The synthesis of silver composites might be a potential
solution to overcome the negative side effects of silver, but
optimizing the concentration of Ag in these composites
remains a challenge. One approach to synthesize silver
composites is to use carbon-based nanomaterials such as:
graphene, carbon nanotubes, and graphene oxide with low
2
concentrations of silver. The synthesis and use of silver-
carbon nanotube complexes as antibacterial material has
been previously reported. Another study reported that car-
bon nanotubes might be toxic due to their contamination
5 with metallic catalysts used in their synthesis.
Graphene quantum dots (GQDs) are among the carbon
nanostructures that may be good candidates for biomedical
applications due to their solubility in aqueous solutions and
high biocompatibility. GQDs are nanostructures of graphene
10 in the size range of 2-20 nm with a set of excellent and
unique chemical and physical properties. In general, GQDs
have no apparent toxicity in vivo, and they have demon-
strated high potential for utilization in cellular imaging, as
antibacterial material, and drug delivery.
15
SUMMARY OF THE INVENTION
According to an aspect of the invention, functionalized
Ag-GQDs nanoparticles were synthesized and a study of
20 their cell toxicity and antibacterial properties is disclosed.
In accordance to another aspect of the invention, silver
nanoparticles are decorated with GQDs, using the resulting
Ag-GQDs to be tailored as an efficient and a safe antibac-
terial material.
25 In accordance with a further aspect of the invention, the
Ag-GQDs inhibited the growth of Gram-positive S. aureus
and Gram-negative P. aeruginosa bacteria.
In accordance with a yet another aspect of the invention,
the decoration of silver nanoparticles with GQDs fostered a
30 synergistic effect that enhanced the antibacterial activity of
silver and minimized its toxicity.
BRIEF DESCRIPTION OF THE DRAWINGS
35 Further features and advantages of the invention will
become apparent from the following detailed description
taken in conjunction with the accompanying figures show-
ing illustrative embodiments of the invention, in which:
FIG. 1 shows a schematic illustration of the synthesis of
4o Ag-GQDs composite, according to the present invention.
FIG. 2 shows a schematic showing an experimental setup
for the synthesis of GQDs nanocomposites by plasma-
assisted approach using a pulsed laser, according to the
present invention.
45 FIGS. 3A and 3B show FE-SEM images of Ag-GQDs,
according to the present invention.
FIG. 3C shows a size distribution histogram of Ag-GQDs,
according to the present invention.
FIG. 3D shows EDS scanned spectrum corresponding to
50 the qualitative elemental composition of Ag-GQDs for the
selected regions shown in the inset, according to the present
invention.
FIG. 4 shows HR-TEM images in scanning mode, accord-
ing to the present invention.
55 FIG. 5A shows Raman spectrum of Ag-GQDs, according
to the present invention.
FIG. 5B shows UV-Visible spectra of bare GQDs and
Ag-GQDs dissolved in nano-pure water at a concentration of
1 mg/mL, according to the present invention.
60 FIG. 5C shows FTIR spectrum of Ag-GQDs showing the
characteristic PEG vibrations of C H and amine groups,
and the hydroxyl groups on the surface of Ag-GQDs,
according to the present invention.
FIG. 6 shows XRD patterns of Ag-GQDs, GQDs and
65 silver powder, according to the present invention.
FIG. 7A shows High resolution XPS spectra of Ag-GQDs
at Cl s, according to the present invention.
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FIG. 7B shows High resolution XPS spectra of Ag-GQDs
at Ag3d, according to the present invention.
FIG. 8 shows MTS cell viability assay of Ag-GQDs and
GQDs in HeLa Cells, according to the present invention.
FIG. 9 shows antibacterial activity of bare GQDs and
Ag-GQDs at different concentrations after 24 hours of
incubation with (A) P. aeruginosa. (B) S. aureus, according
to the present invention.
FIG. 10 shows antibacterial activity of bare GQDs and
Ag-GQDs against (A) P. aeruginosa. (B) S. aureus, accord-
ing to the present invention.
FIG. 11 shows bacterial population growth rate curves of
Ag-GQDs incubated with (A) P. aeruginosa (B) S. aureus,
according to the present invention.
Throughout the figures, the same reference numbers and
characters, unless otherwise stated, are used to denote like
elements, components, portions or features of the illustrated
embodiments. The subject invention will be described in
detail in conjunction with the accompanying figures, in view
of the illustrative embodiments.
DETAILED DESCRIPTION OF THE
INVENTION
Synthesis of the Bare GQDs and Ag-GQDs
Bare GQDs were functionalized with polyethylene glycol
(PEG) as follows. A 0.25 wt % mixture of nickel oxide
powder (Alfa Aesar) and 1.25 wt % of PEG his (3-amino-
propyl) terminated (Sigma Aldrich) in 98.5 wt % benzene
(Sigma Aldrich) was irradiated for 45 minutes with a 1064
nm pulsed Nd:YAG laser (Continuum Surelite II, KDP
doubling crystal, 10 Hz, 10 ns pulse width). The synthesized
GQDs were separated from benzene and the precipitated
nickel oxide by centrifugation at 10000 rpm, following
dissolution in nano-pure water. Finally, the GQDs solution
was purified by using dialysis bags.
For synthesis of Ag-GQDs, a mixture of 0.25 wt % of
silver powder (Sigma Aldrich) and 1.25 wt % of PEG
bis(3-aminopropyl) terminated (Sigma Aldrich) in 98.5 wt
% benzene (Sigma Aldrich) was prepared and irradiated by
pulsed laser, similar to the synthesis of bare GQDs as
illustrated in FIG. 1. The synthesized Ag-GQDs nanopar-
ticles were separated from benzene and dissolved in nano-
pure water, upon purification by using dialysis bags.
In an exemplary embodiment of the invention, 15-100 mg
of silver powder, 10-200 mg of PEG his amino propyl
terminated in 8-50 mL of liquid benzene are mixed and
sonicated for 5 minutes forming a colloidal suspension of
catalysts within the benzene. Then, the suspension is irra-
diated with high energy pulsed laser for 30-60 minutes at
room temperature and atmospheric pressure. The silver
particles are maintained suspended under magnetic stirring
during irradiation. The suspension changes its color from
grey to blackish yellow colloidal suspension. Then, the
synthesized nanoparticles are separated from benzene by
vacuum evaporation. The nanoparticles powder is dissolved
in deionized water, and then sonicated for 1 hour to get a
homogenous yellowish solution in water. Finally, the GQDs
are purified using dialysis bags. The laser used is Nd:YAG
laser with a wavelength of 1064 nm (the laser has a doubling
KDP crystal [10% 532 nm green laser and 90% has a
wavelength of 1064 nm]) and time duration of pulse is 10 ns
(diameter of laser beam in the focusing area is about 0.5
mm). The average energy of laser radiation is in between
25-60 mJ/pulse. Laser radiation power in the maximum of
laser radiation pulse varies in between 25-60 MW (repetition
rate of laser shots is 10 Hz) range of irradiation time 30-60
_►,
minutes, and the time delay between each pulse is 0.1 s. FIG.
2 shows an embodiment of an experimental setup for the
synthesis of GQDs nanocomposites by plasma-assisted
approach using the pulsed laser.
5 Instrumentation and Measurements
High transmission electron microscopy (HR-TEM)
images were recorded using an electronic microscope (JEOL
JEM-2200FS, Japan), operated at 200 kV in STEM mode.
Raman Spectroscopy was carried on using a Horiba Jobin-
io Yvon T-6400 Raman microprobe and a diode Laser with a
wavelength of 532 mu. Fourier transform infra-red spec-
troscopy (FTIR) spectra of the prepared Ag-GQDs/KBr
pellets were measured using a FTIR spectrometer (Thermo
Nicolet iS50, USA) with pure KBr as the background. XPS
15 experiments were performed with Physical Electronics
Instruments (PHI-Quantum 2000, USA), using Al Ka
source. The UV-visible spectra were carried on a spectro-
photometer (Shimadzu 2550, Japan). XRD patterns were
performed with (Rigaku Smart-lab, Japan), equipped with a
20 Cu Ka radiation source, at an accelerating potential of 40 kV
and a tube current of 44 mA. The XRD samples were
prepared by placing a certain powder amount of: bare
GQDs, silver, and Ag-GQDs on a silicon substrates. The
field emission scanning electron microscope (FE-SEM)
25 micrographs were performed with (JEOL JSM-7500F,
Japan), operated at working voltage of 15 W. Energy-
dispersive X-ray spectroscopy (EDS) measurements were
employed in the SEM microscope (JEOL 5800 LV, Japan)
integrated with EDS detector (Oxford Link ISIS Series), and
30 images for the selected zones were recorded at an accelera-
tion voltage of 20 W.
Antibacterial Tests
The antibacterial properties of the nanomaterials were
tested against Gram-negative P. aeruginosa bacteria (ATCC
35 27853) and Gram-positive S. aureus bacteria (ATCC
25923). The inoculum for antibacterial assays was prepared
from actively growing organisms (logarithmic phase). S.
aureus and P. aeruginosa were grown in Mueller Hinton
(MI) broth at 37° C. for 24 and 48 hours respectively.
40 Cultures were centrifuged at 3900 rpm using a centrifuge
(Eppendorf 5810 R, Germany) for 10 minutes. The pellets
were washed twice in PBS and bacterial turbidity was
adjusted to the desired concentration. The bacterial concen-
tration was determined by measuring optical density at 600
45 nm (OD ... )•
The Microdilution Method
The bacterial minimum inhibitory concentration (MIC)
for Ag-GQDs and GQDs were determined based on the
broth microdilution methods, as described in the Clinical
50 laboratory standards guidelines with minor modifications.
MIC is defined as the lowest concentration of an antimicro-
bial that will inhibit the visible growth of a microorganism
after overnight incubation. Briefly, bacterial suspensions
were prepared from overnight culture and adjusted to 10'
55 CFU/mL. Then, a 150 µL of fresh MH broth, 20 µL of
bacterial suspension and 30 µL of different concentrations of
Ag-GQDs and GQDs were added in 96-well plate. A posi-
tive growth control of basal medium without nanoparticles
was included to evaluate the viability of the tested organ-
60 isms. Finally, the microplates were incubated at 37° C. for
24 h under static conditions without shaking. The
microplates were read before and after incubation at OD...
using a microplate reader (Synergy H4 Hybrid).
The Kirby-Bauer Disk Diffusion Method
65 The antimicrobial susceptibility of Ag-GQDs nanopar-
ticles was evaluated using the Kirby-Bauer disk diffusion
method. In brief, a bacterial inoculum with a turbidity
US 9,931,609 B1
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equivalent to 0.5 MacFarland was inoculated evenly onto
the surface of MH agar in petri dishes by swabbing. Sterile
paper disks were saturated with 40 µL solutions of GQDs
(1850 µg/mL) or Ag-GQDs (150 and 320 µg/mL) and then
deposited on the agar surface. For positive inhibition con-
trols, sterile paper disks were saturated with 40 µL solution
containing the antibiotic ampicillin (100 µg/mL) or tetracy-
cline (20 µg/mL) and were used against Gram-positive and
Gram-negative bacteria, respectively. The zones of inhibi-
tion were measured after 24 hours of incubation at 37° C.
Bacterial Population Growth Rate Assay
The bacterial population growth curves ofAg-GQDs were
analyzed using the microplate reader spectrophotometer
(Synergy H4 Hybrid). A bacterial inoculum with a turbidity
equivalent to 0.5 MacFarland was prepared. Then, 150 µL of
fresh MH broth, 20 µL of bacterial suspension and 30 µL of
different concentrations of Ag-GQDs (25, 70, 100, 150 and
320 µg/mL) were added in 96-well microplate. For positive
growth controls, 30 µL of nanoparticles were replaced with
PBS. The reference antibiotic used as negative growth
control with Gram-positive bacteria S. aureus was ampicillin
(100 µg/mL) and tetracycline (20 µg/mL) was used against
the Gram-negative bacteria P. aeruginosa. Microplates were
incubated at 37° C. under linear shaking. The absorbance
was measured at OD60. at intervals of 20 minutes for a total
period of 12-18 hours.
NITS Cell Viability Assay
HeLa cells were cultured in Eagle's minimum essential
medium (ATCC) supplemented with 10% fetal bovine serum
(ATCC), 100 U/mL penicillin, 100 µg/mL streptomycin and
250 ng/mL amphotericin B (Cellgro) at 37° C. with 5% CO2-
The cell viability effects of GQDs and Ag-GQDs nanopar-
ticles were assessed on HeLa cells by using the (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium)-based (NITS) CellTiter 968
AQueous Solution Cell proliferation Assay (Promega,
USA). 2x104 cells were seeded in 96-well plates (Falcon)
and grown overnight. After 24 hours, cell culture medium
was removed and 100 µL of complete cell medium contain-
ing GQDs (25, 70, 100, 150 and 320 µg/mL) and Ag-GQDs
(60, 950, 1850 and 2775 µg/mL) were added. Fresh culture
medium was used as a negative control. After 24 hours of
cells incubation, medium was discarded and 100 µL of fresh
cell medium with 20 µL of NITS reagent was added. Then,
cells were incubated for 30 minutes at 37° C. and centri-
fuged at 2000 g for 10 minutes. Subsequently, the cell
medium containing the NITS reagent was transferred to a
new microplate and the absorbance at 490 mir was measured
with a UV-vis microplate spectrometer (Synergy H4
Hybrid). For data analysis, the results were expressed as %
of cell viability. The equation used was the following:
Abs490 of treated cells% of cell viability= x 100
Abs490 of untreated cells
Half maximal inhibitory concentration (IC5,) was deter-
mined using GraphPad Prism 5 software.
Statistical Analysis
The experiments were performed in triplicates. The
results were expressed as the mean of the standard deviation
of values obtained from at least three independent experi-
ments, differences in mean between experimental group
were analyzed by Student's t-test and (p<0.05) was consid-
ered statistically significant.
6
Results and Discussion
The synthesized Ag-GQDs nanocomposites were fully
characterized using microscopic and spectroscopic tech-
niques, before studying their antibacterial activity. The FE-
5 SEM micrographs in FIGS. 3A and 3B show that Ag-GQDs
are in the range of 8-70 mu. The histogram in FIG. 3C
depicts the average size distribution of the synthesized
nanoparticles, based on the analysis carried out for 5 dif-
ferent fields chosen randomly. FIG. 3D reveals the qualita-
tive elemental composition of Ag-GQDs using the EDS
10 
technique, at the selected regions shown in the inset. The
EDS spectrum indicates the presence of carbon, silver and
silicon. The presence of silver and carbon are attributed to
the Ag-GQDs and the silicon peak arises from the substrate,
where the nanoparticles were placed for the microscopic
15 characterizations. The data obtained confirm that the syn-
thesized nanoparticles are a composite of carbon-silver.
HR-TEM microscopy was employed to give complemen-
tary information related to the size, morphology and crys-
talline structure of Ag-GQDs, in addition to the FE-SEM
20 data obtained above. The HR-TEM micrographs of bare
GQDs in FIG. 4 (image A) depict their size range of 1.6-4
mu, and lattice spacing of 0.214 nm that corresponds to the
(100) lattice fringes of graphene. FIG. 4 (image B) displays
a single Ag-GQDs nanoparticle. The nanoparticle of the
25 composite shows a diameter of 10 nm with an inter-planar
spacing of 0.145 nm that matches with the (220) plane of
silver. Some nanostructures were observed on the surface of
the silver nanoparticle with a lateral diameter of 1.6-2 mir
and the same 0.214 mir inter-planar spacing of graphene
30 (100) shown in FIG. 4 (image A). In order to obtain more
information about the composite, we employed the dark
field to get the high contrast of the clusters FIG. 4 (image Q.
The image in the inset of image C shows clusters of
nanoparticles in the range of 50-100 mir and other nanopar-
35 ticles less than 20 mu. It can be clearly observed that the
nanoparticles of silver and GQDs are packed together form-
ing the core, which is coated by the PEG shell. FIG. 4 (image
D) confirms the presence of bare GQDs inside the PEG
shell, when the selected region in the dotted rectangle in
40 image C was magnified. The fact that Ag-GQDs nanopar-
ticles come together in the PEG shell forming clusters
explains the wide size distribution observed in the data
obtained in FE-SEM images.
To characterize the carbon nanostructures synthesized in
45 the nanocomposites, Raman spectroscopy was employed.
The Raman spectrum in FIG. 5A shows the presence of
D-band at 1353 cm-', which arises from the disorder in sp2
hybridized carbon, and the G-band at 1594 cm-' of the
graphitic structures. The spectrum is in good agreement with
50 the spectrum corresponding to synthesized GQDs, reported
elsewhere.
UV-Visible spectra of GQDs and Ag-GQDs in FIG. 5B
reveal an absorption at ca. 270 mu, which is observed in
graphene, and GQDs, and is attributed to 71-70 transition of
55 aromatic sp2 domains. The absorption observed in the Ag-
GQDs spectrum at ca. 420 nm corresponds to the localized
surface plasmon of silver. The UV-Visible data are consis-
tent with the EDS results described above.
The conjugation of Ag-GQDs with PEG was further
60 characterized using FTIR spectroscopy. In FIG. 5C, the
peaks present in the FTIR spectrum of Ag-GQDs are
assigned as follows: 2850-3000 cm-' (MHz stretching),
1635 cm-' (N H bending), 1580 cm-' (C —C aromatic
bending), 1460 cm-' (C —H bending), 1107 cm-'
65 (C-0--C stretching) and 600-900 cm-' (N H wagging).
The existence of these vibrations indicates the successful
conjugation of Ag-GQDs with PEG. The conjugation of
US 9,931,609 B1
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PEG on the surface of Ag-GQDs is important in increasing
the stabilization, solubility and biocompatibility of the nano-
composites.
XRD spectroscopy was analyzed to reveal the crystalline
structure of Ag-GQDs and validate the other characteriza-
tion results. XRD patterns were obtained for the bare GQDs,
silver powder used in the synthesis, and the Ag-GQDs (FIG.
6). In the XRD pattern of silver, the peaks at 38.1°, 44.3°,
64.5° and 77.5° are assigned to the crystallographic planes
(111), (200), (220) and (3 11) of the face-centered cubic (fcc)
Ag nanoparticles, respectively, according to the 7CPDS card
No. 04-0783. For the bare GQDs, the peak at 26.61 is
commonly observed and corresponds to the d-spacing of the
basal plane (002) of graphite. The peaks shown at 18.97°,
23.3° and 35.7° are attributed to PEG, which is conjugated
on the surface of bare GQDs, and match with the PEG peaks
reported by El Moussaoui et al. As expected, the combina-
tion of the observed peaks in silver, PEG and GQDs in the
XRD pattern arise in the pattern of Ag-GQDs nanocompos-
ites. The XRD results are consistent with the HR-TEM,
UV-Visible, FTIR, Raman and FE-SEM data described
above.
The XPS technique was employed to quantify the
approximate elemental composition attributed from silver
and carbon in atomic percent (%). The XPS analyses indi-
cate that the attribution of silver and carbon are approxi-
mately 33.4 and 66.6%, respectively. The deconvolution of
the high resolution XPS spectrum at CI s in FIG. 7A reveals
the presence of amine, hydroxyl, ether and carboxyl groups
at 285.7, 286.7, 287.5, 289.0 eV, respectively. FIG. 7B
shows the existence of bands at 368 and 374 eV correspond-
ing to Ag3d of the Ag-GQDs. In addition, the difference in
binding energy between the peak Ag3d512 and Ag3d312 is 6
eV, which confirms that the silver in the nanocomposites is
metallic silver. The XPS data are in agreement with the FTIR
and XRD data discussed above.
According to an important aspect of the invention, the
Ag-GQDs is synthesized for use in the biomedical field and
it is imperative to evaluate their biocompatibility in mam-
malian cells. The cell viability of HeLa cells at different
concentrations of bare GQDs and Ag-GQDs after 24 hours
of incubation (FIG. 8) was tested. The results show that cell
viability was maintained at 100% for cells incubated with
the bare GQDs at concentrations up to 2775 µg/mL (FIG. 8).
In the case of Ag-GQDs, they did not affect cell viability at
concentrations lower than 200 µg/mL and the IC50 is 250
µg/mL. The IC50
 
for Ag-GQDs is around 83.5 µg/mL, which
is significantly higher than the IC50 values in the range of
1.5-56.4 µg/mL reported for Ag nanoparticles alone. This
result indicates that the GQD coating helps to reduce the
effective toxicity Ag nanoparticles.
The antibacterial activity of bare GQDs and Ag-GQDs
was evaluated at different concentrations against P. aerugi-
nosa and S. aureus using the microdilution method (FIG. 9).
The bacterial inoculum used in this assay was 107 CFU/mL
for both bacterial strains, and the concentration of nanopar-
ticles were the same as those used for the mammalian cell
viability assays described above. Table 1 below summarizes
the MIC values required of bare GQDs and Ag-GQDs to
inhibit both bacterial strains. A total inhibition of P. aerugi-
nosa was observed when Ag-GQDs and GQDs were used at
concentrations of 150 µg/mL and 1850 µg/mL, respectively,
as shown in Table 1. On the other hand, the Gram-positive
bacteria S. aureus showed more resistance to Ag-GQDs and
GQDs in terms of the concentrations needed for their total
inhibition, i.e. the required concentration of Ag-GQDs was
320 µg/mL and for GQDs higher than 2775 µg/mL (Table 1).
8
It has been suggested in previous studies that the increment
in the resistance of the Gram-positive bacteria could be
associated to the thicker cell wall, which protects cells from
nanoparticle penetration into the cytoplasm.
5
TABLE 1
10
MIC (µg/mL)
Tested Sample P. aeruginosa S. aureus
GQDs 1850 >2775
Ag-GQDs 150 320
Furthermore, the antibacterial activity of Ag-GQDs and
15 bare GQDs was validated using the Kirby-Bauer method as
shown in FIG. 10, wherein: (1) Negative Control, (2)
Ag-GQDs 150 µg/mL, (3) Ag-GQDs 320 µg/mL, (4) Posi-
tive controls: Tetracycline 20 µg/mL in (A) or Ampicillin
100 µg/mL in (B) and (5) GQDs 1850 µg/mL. Table 2 below
20 
summarizes the diameter of the inhibition zones exhibited
by the diffusion of Ag-GQDs and bare GQDs against S.
aureus and P. aeruginosa, as shown in FIG. 10. In this
method, paper disks were impregnated with 40 µL from
solutions of Ag-GQDs at concentrations of 150 and 320
25 
µg/mL. Ag-GQDs inhibited both bacterial strains at both
concentrations, and the inhibition zones at the lowest con-
centrations are 10.4 and 9.6 mm for P. aeruginosa and S.
aureus, respectively. In contrast, the bare GQDs exhibited a
mild antibacterial behavior against both Gram-positive and
30 Gram-negative bacteria. The Kirby-Bauer data obtained for
both Ag-GQDs and GQDs are consistent with the results
obtained from the microdilution method. Moreover, both
sets of data reveal that GQDs have an intrinsic antibacterial
behavior, unlike previous reports which concluded that
35 GQDs can only be used as antibacterial material under
specific conditions, such as excitation with 470-nm radia-
tion, or in combination with HzOz.
IIG1.3N1WJ
40 Inhibition zone (mm)
Tested Sample P. aeruginosa S aureus
Negative Control
Ag-GQDs (150 µg/mL) 10.4 ± 0.1 9.6 ± 0.2
45 Ag-GQDs (320 µg/mL) 13.2 ± 0.2 12.2 ± 0.1
GQDs (1850 µg/mL) 10 ± 0.1 9 ± 0.1
Positive Control 8.6 ± 0.2 35 ± 0.3
The results obtained from the microdilution and Kirby-
5o Bauer methods led us to study the inhibition rate of both
bacterial strains when treated with Ag-GQDs nanocompos-
ites. The bacterial population growth versus time in the
presence of Ag-GQDs was evaluated as shown in FIG. 11.
Ag-GQDs nanocomposites induced a delay of 13 hours in
55 the growth time of P. aeruginosa for the MIC of 150 µg/mL
and a 4 hours delay in the growth time of S. aureus at the
MIC of 320 µg/mL.
Notably, in all the antibacterial activities experiments to
evaluate Ag-GQDs and GQDs, the used inoculum size was
60 in the range of 10'-10$ CFU/mL, which is higher than the
common inoculum 105 CFU/mL used at routine evaluations
of antibiotics. While previous studies showed a similar
reduction in the bactericidal properties of antibiotics, and in
particular when the size of the inoculum used in the evalu-
65 ation is 2_108 CFU/mL, the synthesized Ag-GQDs presented
good antibacterial properties against Gram-positive and
Gram-negative bacteria.
US 9,931,609 B1
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The present invention provides the successful synthesis of
biocompatible nanocomposites of Ag-GQDs. The nanocom-
posites consists of silver nanoparticles decorated with GQDs
on their surface. The Ag-GQDs inhibited the growth of
Gram-positive S. aureus and Gram-negative P. aeruginosa
bacteria, which are commonly isolated from microbial infec-
tions in wounds. The experiments results showed the suc-
cessful use of Ag-GQDs in inhibition of both bacterial
strains when tested with a bacterial inoculum at high con-
centration. An optimal concentration of 150 µg/mL would
inhibit both types of bacterial growth without affecting
mammalian cell viability. The decoration of silver nanopar-
ticles with GQDs fostered a synergistic effect that enhanced
the antibacterial activity of silver and minimized its toxicity.
These results indicate that Ag-GQDs nanocomposites may
be applied as antibacterial material, such as in: antibiotics,
coating of surgical instrumentation, wound dressing textiles,
disinfectants and detergents.
Although the invention has been described in conjunction
with specific embodiments, it is evident that many alterna-
tives and variations will be apparent to those skilled in the
art in light of the foregoing description. Accordingly, the
invention is intended to embrace all of the alternatives and
variations that fall within the spirit and scope of the
appended claims.
We claim:
1. A method of synthesizing functionalized Nanoparticle-
Graphene Quantum Dots nanocomposites (NP-GQDs) com-
prising:
irradiating with a source of electromagnetic radiation a
mixture containing a compound serving as a source of
carbon, a powder serving as a precursor of a nanocom-
posite core and a ligand source, effectively synthesizing
Nanoparticle-Graphene Quantum Dots nanocompos-
ites having a core decorated with Graphene Quantum
Dots and functionalized with said ligand.
2. The method of claim 1, wherein ligands are attached to
at least one of: the nanocomposite core and the Graphene
Quantum Dots.
3. The method of claim 1, wherein the compound serving
as a source of carbon is hydrocarbon.
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4. The method of claim 3, wherein said hydrocarbon is
selected from the group consisting of: benzene, toluene and
glycerol.
5. The method of claim 1, wherein the ligand source is a
5 polymer.
6. The method of claim 5, wherein said polymer is
selected from the group consisting of: polyethylene glycol
(PEG) and polyethylenimine (PEI).
7. The method of claim 1, wherein said powder comprises
10 at least one of: an elemental metal powder, an elemental
semiconductor powder, a metal oxide powder and a semi-
conductor oxide powder.
8. The method of claim 7, wherein the metal is selected
from the group consisting of: silver, gold, copper, zinc,
15 cobalt, iron, and ruthenium.
9. The method of claim 7, wherein the semiconductor is
selected from the group consisting of: silicon and germa-
nium.
10. The method of claim 1, wherein the compound serving
20 as a source of carbon, the powder and the ligand are
combined in a liquid suspension.
11. The method of claim 1, wherein the Nanoparticle-
Graphene Quantum Dots nanocomposites are soluble in
organic and polar solutions.
25 12. The method of claim 1, wherein the source of elec-
tromagnetic radiation is a laser.
13. The method of claim 12, wherein said laser is an
Neodymium-doped Yttrium Aluminum Garnet (Nd:YAG)
laser.
30 14. The method of claim 1, wherein the size of said
Graphene Quantum Dots is between 2 and 10 mu.
15. The method of claim 1, wherein the size of said
Nanoparticle-Graphene Quantum Dots (NP-GQDs) nano-
composites is between 5 and 100 mu.
35 16. The method of claim 1, wherein the concentration of
the ligand source is between 0.1-10 mg/mL.
17. The method of claim 1, wherein the concentration of
the powder is between 0.1-10 mg/mL.
18. The method of claim 1, wherein said mixture is
40 irradiated with a power density between 10$-1010 W CM-2.
